QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 0.355
-- x --
-- x --
-- - --
$ 0.26 - $ 0.98
545,164
na
81.27M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-19-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-06-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 02-06-2018 12-31-2017 10-Q
32 11-07-2017 09-30-2017 10-Q
33 09-01-2017 06-30-2017 10-K
34 05-08-2017 05-02-2017 10-Q
35 02-06-2017 12-31-2016 10-Q
36 11-08-2016 09-30-2016 10-Q
37 09-13-2016 06-30-2016 10-K
38 05-10-2016 03-31-2016 10-Q
39 02-08-2016 12-31-2015 10-Q
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vaxart-withdraws-its-reverse-stock-split-proposal

Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...

 vaxarts-second-generation-oral-norovirus-vaccine-shows-up-to-25-fold-increase-in-protective-fecal-iga-in-phase-1-trial

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against i...

 vaxart-q2-eps-007-beats-009-estimate-sales-39730m-beat-2023m-estimate

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19....

 vaxarts-earnings-a-preview
Vaxart's Earnings: A Preview
08/12/2025 19:02:15

 vaxart-announces-its-common-stock-has-been-approved-to-trade-on-the-otcqx-best-market

Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...

 vaxart-reports-topline-results-from-phase-1-clinical-trial-evaluating-second-generation-oral-pill-norovirus-vaccine-constructs-head-to-head-against-its-first-generation-constructs

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antib...

 vaxart-board-commits-to-high-end-of-1-for-20-reverse-stock-split-ratio

-SEC Filing

 vaxart-receives-barda-approval-to-initiate-dosing-in-10000-participant-portion-of-ongoing-phase-2b-clinical-trial-evaluating-oral-pill-covid-19-vaccine-candidate

Vaxart, Inc. (NASDAQ:VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development ...

 vaxart-publishes-complete-data-from-phase-2b-challenge-study-of-first-generation-oral-pill-norovirus-vaccine-candidate-in-science-translational-medicine

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral sheddingMachine learning a...

 vaxart-appoints-jeroen-grasman-as-cfo-effective-may-19-2025-grasman-succeeds-phillip-lee

- Mr. Grasman brings over two decades of biotech financial leadership experience -SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GL...

 vaxart-q1-eps-007-beats-010-estimate-sales-2088m-beat-955m-estimate

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION